北美医药市场 Omega-3 成分 - 行业趋势和 2030 年预测

北美 Omega-3 医药原料市场分析及规模

欧米伽-3 成分越来越受到重视，并成为该地区消费者日常饮食的一部分。目前，正在进行大量研究，预计这将为多家制造商创造竞争优势，以开发用于药品的新型创新欧米伽-3 成分。据估计，70% 的美国人使用互联网获取有关欧米伽-3 成分的健康信息，这反过来又促进了对欧米伽-3 成分的需求增长。  

Data Bridge Market Research 分析了 2023-2030 年预测期内医药市场 omega-3 成分的增长率。在上述预测期内，医药市场 omega-3 成分的预期复合年增长率约为 11.6%。2022 年市场价值为 3.812 亿美元，到 2030 年将增长至 9.172 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

北美 Omega-3 药品成分市场范围和细分

Market Definition

Omega 3 ingredients are naturally occurring polyunsaturated fatty acids and nutrients that are essential for optimal human health. There are three kinds of omega 3 ingredients, namely, eicosapentaenoic acid (EPA), alpha-linoleic acid (ALA), and docosahexaenoic acid (DHA). EPA and DHA are mostly extracted from fish and ALA is mainly extracted from plants sources such as seeds and nuts.

North America Omega-3 Ingredients for Pharmaceuticals Market Dynamics

Drivers

• Increasing Demand for Dietary Supplements

The omega-3 demand is increasing in the health supplement segment, since it provides the same benefit as that of fish oil, but with no off-odour or taste. Omega-3 is considered to be more sustainable and bioavailable. The algae omega-3 ingredient market is boosted by the demand for dietary supplement products. The increased use of premium-grade omega-3 for infant formula is another primary factor enhancing the market, as algae omega-3 has proved to be of superior quality. Thus, this factor increases the growth of the market.  

• Increasing Demand of Docosahexaenoic acid (DHA)

Docosahexaenoic acid (DHA) type is in higher demand due to the increasing utilization of the product in infant formulas for the betterment of an infant's overall health. In the human diet, DHA is the most vital and abundant omega-3 fatty acid, which helps in maintaining the overall health of the human body. DHA is a main component for the development and maturity of an infant's brain and eyesight. Furthermore, it is extensively used in nutritional supplements and fortified foods. It is also widely used in treating dementia, coronary artery disease (CAD), attention deficit hyperactivity disorder, and Type 2 diabetes. DHA helped in increasing f longevity have also resulted in its use in elderly nutrition products. Thus, this factor increases the growth of the market.  

Opportunities

• Huge growth in concentrated forms of algal omega-3 ingredients

New ultra-high concentrated omega-3 ingredients offer several benefits to consumers willing to pay a higher premium price for high-end products. Several suppliers are investing in the production of high concentrated algal omega-3 products, estimating increased demand to drive the sales. The market for concentrates has also been increasing, as more consumers become aware of the benefits of algal omega-3 and seek the benefits of higher doses. Several major companies are involved in omega-3 manufacturing that has started to strategically capitalize the existing business expansion opportunity.

• Rising Research Activities

Numerous research studies have developed a link between consumption of fatty fish and lowering of coronary heart diseases. For instance, fish oils are widely used as a supplement to balance the required dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Furthermore, fish oil is normally recommended as a supplement product for people who suffer from myocardial infarction by the American Heart Association, World Health Organization (WHO), the National Heart Foundation of Australia and National Health and Medical Research Council (NHMRC). Thus, this factor helps to create much opportunities for the growth of the market.

Restraints/Challenges

• Difficulty in Inconsistent Guidelines

The lack of inconsistent standards and guidelines in the global EPA/DHA (Omega3) ingredients market is also one of the major factors that limit the market growth. Regulations vary from country to country with regards to the use of EPA / DHA (Omega 3) and its major inclusion under the food category. Also, lack of regulations cause misuse of claims indicating health benefits. Thus, this factor hamper the market growth.

• Increasing Negative Consumer Perception About omega-3 ingredients

Negative consumer perception associated with the smell and taste of omega-3 ingredients is also anticipated to limit the growth of the market. These unstable fatty acids can damage through enzymatic or chemical oxidation to form compounds that give foods a fishy smell. Additionally, fresh fish oil has no fishy taste or smell, just like fresh fish. People feel hesitant to adopt for omega-3 ingredients. Thus, this hampers the market growth.

这份用于药品的 omega-3 成分市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入来源、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新等方面的机会。如需了解有关用于药品的 omega-3 成分市场的更多信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

近期发展

• 2020 年，ANI Pharmaceuticals, Inc. 推出了 omega-3-酸乙酯胶囊 USP，用于降低患有严重（大于或等于 500mg/dL）高甘油三酯血症 (HGT) 的成年患者的甘油三酯 (TG) 水平。该公司通过增加其产品组合并吸引更多客户而受益。
• 2019年，Croda International Plc 与博士学者共同致力于开放式创新计划的创新和发展，研究计划的实施使公司的全球销售额和利润均大幅增长。

北美 Omega-3 药品成分市场范围

医药市场中的 omega-3 成分根据来源、类型、形式、治疗领域、人群类型和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

来源

• 海洋
• 植物

类型

• 二十二碳六烯酸 (DHA)
• 二十碳五烯酸(EPA)
• 亚麻酸 (ALA)

表格

• 液体
• 干燥

治疗领域

• 心血管疾病
• 自身免疫性疾病
• 骨骼和关节疾病
• 神经系统疾病
• 眼科疾病
• 皮肤健康
• 癌症
• 其他的

人口类型

• 成年人
• 孩子们

分销渠道

• 直接的
• 间接

医药市场 Omega-3 成分区域分析/见解

对药品市场的 omega-3 成分进行了分析，并按来源、类型、形式、治疗领域、人群类型和分销渠道提供了市场规模洞察和趋势。

药品市场 omega-3 成分报告涉及的主要国家 是北美的美国、加拿大和墨西哥。

在整个预测期内，北美的 Omega-3 成分医药市场一直呈现正增长态势，因为用于预防心血管疾病的含有 Omega-3 成分的医药产品的使用量不断增加。由于人们越来越意识到食源性疾病的增加以及食品工业的不断发展，北美对健康食品的需求不断增加，预计在预测期内将推动北美市场的增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和北美 Omega-3 医药原料市场份额分析

药品用 omega-3 成分市场竞争格局提供了按竞争对手划分的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对药品用 omega-3 成分市场的关注有关

药品用 Omega-3 成分市场的主要参与者包括：

• Avestia Pharma（印度）
• Novasep（法国）
• AbbVie Inc.（美国）
• KD制药集团（日本）
• 巴斯夫公司（德国）
• Corbion（荷兰）
• 帝斯曼（荷兰）
• 阿斯利康（英国）
• 葛兰素史克公司（英国）
• 费森尤斯卡比公司（德国）
• Croda International Plc（美国）
• AMARIN CORPORATION（爱尔兰）
• ANI Pharmaceuticals, Inc.（美国）
• Epax（挪威）
• Strides Pharma Science Limited（印度）
• Pharma Marine AS（挪威）
• KinOmega Biopharm Inc. (中国)
• Camber Pharmaceuticals, Inc.（美国）

SKU-55586